Parenteral Packaging. Container CIosure Best Practices Throughout the Product Life Cycle February 2018 Marriott Rome Park Hotel Rome Italy

Transcription

1 PDA Europe Conference, Exhibition, Education The Parenteral Drug Association presents: Parenteral Packaging Container CIosure Best Practices Throughout the Product Life Cycle February 2018 Marriott Rome Park Hotel Rome Italy

2 LETTER FROM THE CHAIRS Dear Colleagues, You are warmly invited to join us in our ongoing professional discourse of latest manufacturing technologies and business trends in the Parenteral Packaging arena. PDA Europe s Conference has proven to be a must-attend event for professionals in this field. Join us in Rome / Italy, February 2018 to continue and further deepen scientific advancements and understanding of topics previously raised in this successful annual event. As proper packaging of pharmaceuticals is crucial to drug stability, this conference and the accompanying exhibition address quality of components and containers as much as aspects of processing, product distribution and storage. Excellent speakers from the industry, regulation and academia will give detailed information about opportunities and challenges the advancing pharmaceutical packaging market faces. The conference aims to keep its attendees updated about all regulatory aspects involved in the parenteral packaging process, such as new regulations from European and US agencies, the revision of Annex 1, and PDA Technical Reports. Different materials such as glass, polymers & elastomers and their characteristics regarding supplier issues and end-user preferences will also be discussed, as well as the design of primary and secondary packaging. SCIENTIFIC PLANNING COMMITTEE Roger Asselta, Chair, Genesis Packaging Roman Mathaes, Chair, LONZA Bettine Boltres, WEST Derek Duncan, LIGHTHOUSE Claudia Heinl, SCHOTT Renaud Janssen, Datwyler Enric Jo, ReigJofre Laboratories Galen Shi, Eli Lilly Michael Spallek, Rommelag ENGINEERING Daniel Wagner, Sanofi Klaus Wuchner, Janssen-J&J Jörg Zürcher, Bayer Kerstin Wilken, PDA Europe The role of Container Closure Integrity (CCI) in product-package development, post-approval product changes and routine manufacturing will be explored, and information on aseptic processing will be given. Of equal importance to the content is to interact with the speakers and your fellow attendees. Rome will offer a comfortable yet exciting atmosphere for exchange during refreshment breaks, on-site lunches and evening receptions. Join PDA Europe s Parenteral Packaging Conference in one of the most beautiful cities in the world. Welcome to Rome! Roger Asselta, Chair, Genesis Packaging Roman Mathaes, PhD Chair, LONZA 2 pda.org/eu/parpack2018

3 WELCOME TO ROME SCHEDULE AT A GLANCE 26 February 10:00 17:00 Pre-filled Syringes Interest Group Meeting 26 February 13:00 18:00 Packaging Science Interest Group Meeting 27 February 9:00 18:30 Parenteral Packaging Conference, Exhibition 27 February 18:30 22:00 Sightseeing Tour & Networking Dinner 28 February 9:00 16:30 Parenteral Packaging Conference, Exhibition 1 March 9:00 17:00 Container Closure Development Training Course 1 March 2 March 9:00 17:30 8:30 16:30 Container Closure Integrity Testing Workshop 1 March 2 March 9:00 18:00 9:00 16:30 Extractables & Leachables Training Course For latest information, please visit: pda.org/eu/parpack2018 pda.org/eu/parpack2018 3

4 INTEREST GROUP MEETING 26 February 2018, 10:00-17:00 Pre-filled Syringes 2018 Focus Topic: Improving Patient Safety and Convenience Dear Colleagues, We continually strive to develop devices that improve upon current standards of safety, provide ease of administration, and offer convenience for the end user. Be it a pre-filled syringe, pen, or auto-injector the industry trend is toward fill& finish of smaller batches and larger volumes that meet the ever-increasing quality requirements that support patient safety. The goal of this meeting is to discuss these issues with a primary focus on: 1. Challenges associated with large volume injections that either help reduce the number of injections, or actually change the route of administration from IV to SC. 2. Identification of trends and approaches in manufacturing such as the need for smaller batches, different containers and greater flexibility in fill & finish technologies. 3. Acquiring knowledge about the most up-to-date approaches related to Quality including container/ drug interaction, zero particles, avoidance of stopper movement during air shipment, and much more. Take advantage of the open forum design offered by the small Interest Group meeting approach. Hear presentations from leading experts, interact and discuss your experiences with colleagues in round table discussions, and receive the latest information about activities of the PDA Interest Group Pre-filled Syringes. IG Leader Brigitte Reutter-Haerle, Vetter Pharma International GmbH, Interest Group Leader Europe Brigitte Reutter-Haerle is the Vice President of Marketing / Corporate Communications for Vetter, a leading contract development and manufacturing organization that serves the global pharma/biotech industry. She was called to this new position in September 2014 and is responsible for the company s international marketing activities, product and service management as well as HR marketing and internal communication. Between 2004 and 2014, she obtained the position of Director Corporate Marketing. In 2009, she led the communications program for Vetter s U.S. expansion. Ms. Reutter-Haerle joined Vetter in 1996, serving in the company s sales and marketing function, and transferred to corporate marketing three years later. She began her career in 1983, holding various positions in the sales organizations of firms including Hilton International and TNT Express Worldwide. Ms. Reutter-Haerle earned a B.A. and a degree in Business Administration from Baden-Wuerttemberg Cooperative State University. She has been leading the Pre-filled Syringe Interest Group/Europe of the Parenteral Drug Association since pda.org/eu/parpack2018

5 AGENDA 17 Jan 2018 Monday, 26 February :00 17:00 10:00 Welcome and Introduction Falk Klar, PDA Europe Brigitte Reutter-Härle, VETTER Support Patient Safety and Convenience Moderator: Brigitte Reutter-Härle, VETTER 10:15 Importance of Suppliers and CMOs for Quality of Pre-filled Syringes Mauro Giusti, Eli Lilly Italia 10:45 How to Reduce the Overall Particle Content in Pharmaceutical Packaging for Parenterals: Lessons Learnt and Practical Cases Alessandro Morandotti, Ompi-Stevanato Group 11:15 Approaching the Goal of Zero Particles in the Production Line Piotr K. Wagner, West Pharmaceutical Services 11:45 Coffee Break & Exhibition 12:15 Case Study: Advanced Syringe Technology for Silicone Sensitive Protein Drugs 12:45 Impact of Sterilization Method on Protein Aggregation and Degradation in Polymer Pre-filled Syringes Christian Herget, BD Pharmaceutical Systems Philippe Lauwers, Terumo Pharmaceutical Solutions 13:00 Lunch Break & Exhibition PDA Interactive: Roundtable Discussions 14:15 Wearable Large Volume Injectors - The Challenge of Accurate Dosing 14:45 Topic 1 Particles Assessment of Associated Risks and Means for Further Reduction of Particulate Matter Moderators: Christian Herget, BD Pharmaceutical Systems William Dierick, Terumo Pharmaceutical Solutions 15:15 Groups Switch Topic 2 - Wearables Paul Senn, Sensile Medical Topic 2 Wearables: Demands on wearable injectors: patient interface, patches, drive mechanisms and drug containment Moderator: Ian Thompson, Ypsomed Groups Switch Topic 1 Particles 15:45 Coffee Break & Exhibition 16:15 Identification of Trends and Approaches in Manufacturing: Small batches, container variety and greater flexibility in fill & finish technologies Giandrea Favetti, Alfasigma 16:45 Summary: Q&A, Discussion 17:00 Conclusion of Interest Group Meeting pda.org/eu/parpack2018 5

6 INTEREST GROUP MEETING 26 February 2018, 13:00-18:00 Packaging Science Joint EU & US Interest Group Meeting Please be invited to contribute to this open forum and discuss latest approaches, exchange experience, and share technology updates on these and any other topics related to Packaging Science! Annex 1 Revision & CCI Testing and Batch Release Process Monitoring Packaging & Formulation Interactions Coated / Multi-layer vials IG Leaders EU Bettine Boltres, PhD WEST Derek Duncan, PhD LIGHTHOUSE IG Leader US Roger Asselta, Genesis Packaging Don t miss the 3 rd PDA Europe Annual Meeting Global Healthcare of the Present & the Future Register by 29 April 2018 and SAVE! pda.org/eu/annual pda.org/eu/parpack June 2018 Marriott Hotel Berlin Germany

7 PDA Europe Conference, Exhibition, Education The Parenteral Drug Association presents: Vaccines pda.org/eu/vaccines2018 Register by 4 March 2018 and SAVE! April 2018 Málaga Spain pda.org/eu/parpack2018 7

8 FLOOR PLAN Smithers IWATA MACHINERY BOOTH Tasitest SPONSOR WORKING LOUNGE Rommelag Kisico OMPI Genesis Packaging Terumo Corning PTI WILCO Lonza AMRI WEST Schott Lighthouse Toxikon Gerresheimer POSTER SESSION ENTRANCE 8 pda.org/eu/parpack2018

9 TO EXHIBIT: PDA meetings and conferences are a great opportunity for your company to gain on-site exposure in front of highly-qualified, upperlevel professionals in the pharmaceutical and biopharmaceutical industry. Exhibition and Sponsorship Opportunities are available. A basic exhibition package for this event is priced Euro net (table-top). For more information please contact expo-europe@pda.org Conference Room Table Top 2 m x 4 m (8 m 2 ) Table Top sold Catering Working Lounge Machinery Booth 4 m x 4 m (16 m 2 ) Poster Session PDA Registration pda.org/eu/parpack2018 9

10 CONFERENCE AGENDA Tuesday, 27 February Jan :00 Welcome and Introduction Kerstin Wilken, PDA Europe OPENING PLENARY Roger Asselta, Genesis Packaging Roman Mathaes, LONZA Session 1 International Regulatory Updates Moderator: Derek Duncan, LIGHTHOUSE 9:15 Annex 1 Revision & CCIT Andrew Hopkins, MHRA 9:45 Secondary Packaging Considerations & Last Mile Distribution Umit Kartoglu, WHO 10:15 A Risk-based Approach for Assessment of Pharmaceutical Packaging of Parenterals - A Regulatory Perspective Charudharshini Srinivasan, US FDA 10:45 Q&A, Discussion 11:15 Coffee Break, Poster Session & Exhibition Session 2 Packaging Technology Updates Moderators: Roman Mathaes, LONZA 11:45 Usability of Glass versus Polymer Ampoules: A Comparison Michael Spallek, Rommelag 12:15 Impact of Drug Formulation Variables on Packaging Functionality Galen Shi, Eli Lilly 12:45 Engineering Considerations: Pressure and Strain Waves in Pre-Filled Syringes during Auto-Injector Activation Julian Jazayeri, Amgen Jean-Christophe Veilleux, California Institute of Technology 13:15 Q&A, Discussion 13:45 Lunch Break, Poster Session & Exhibition The PDA is proud to invite you to a very special Networking Event Tuesday, 27 February :30h Meeting Point: Hotel Lobby Joint Bus Transfer including Sightseeing Tour of Rome 20:00h Dinner, Ristorante Venerina, Borgo Pio n 38, Roma :00h Departure Bus Transfer to Conference Hotel 10 pda.org/eu/parpack2018

11 PARALLEL TRACKS Session 3 Track A Track B Manufacturing Process Moderator: Daniel Wagner, Sanofi 14:45 Investigations Carried Out on Clean Room Injection Molding of Plastic Components for Parenteral Packaging Reinhard Steger, Braunform 15:15 From Blow-Fill-Seal Ampoules to Advanced Container Closure Systems by Blow-Fill-Insert- Seal: A review based on three case studies Otto Schubert, Rommelag Packaging Material: Glass Moderator: Claudia Heinl, SCHOTT Reduction of Particulate Contamination Generated During Bulk Vial Filling Christopher Timmons, Corning Extractables Profiles of Borosilicate and Aluminosilicate Glass A Comparison Folker Steden, Schott 15:45 Coffee Break, Poster Session & Exhibition 16:15 Case Study: Mid-Scale Production Line for Aseptic Filling and Sealing of IV-Bags Bernhard Brugger, Harro Hoeflinger 16:45 Filling and Stoppering Processes for Cartridges and Syringes Klaus Ullherr, Robert Bosch Packaging 17:15 Critical Time- & Temperature- Dependent Container Closure Integrity (CCI) Through the Sealed Drug Product Life Cycle Qingyu Zeng, West Lyophilization of Nested Glass Containers: Process Investigation Lorenza Bonaldi, Stevanato Fused Quartz Vials for Enhanced Chemical Stability Ben Gauthier, Momentive Glass Packaging Breakages: A New Testing Protocol for the Optimization of Container Filling Lines Nicola Favaro, Stazione Sperimentale del Vetro 17:45 Q&A, Discussion Q&A, Discussion 18:30 Networking Dinner incl. Sightseeing Tour of Rome Join us for a fabulous evening in a traditional Roman Restaurant. pda.org/eu/parpack

12 CONFERENCE AGENDA Wednesday, 28 February 2018 Session 4 Regulatory Updates Moderators: Roger Asselta, Genesis Packaging 9:00 USP Updates Bettine Boltres, USP 9:25 Elastomeric Closures - Regulatory Updates Renaud Janssen, Datwyler 9:50 ISO Norms Update: Rigid Container Systems and Related Accessories for Parenterals and Injectables ISO/TC 76/WG2 Volker Rupertus, SCHOTT 10:15 Coffee Break, Poster Session & Exhibition PARALLEL TRACKS Session 5 Track A Track B Container Closure Integrity & Testing Moderator: Bettine Boltres, WEST 10:45 A Case Study to Address a Gap in the Device-to- Vial Interface: Stopper Push-in by Chemo Spikes An Overlooked Oncology Safety Risk Cathy Zhao, West 11:10 Container Closure Integrity: Specific Strategies for Unique Applications Oliver Stauffer, pti 11:35 Proposal for Implementing the RSF Tester in a Manufacturing Environment Robert Ovadia, Genentech 12:00 Development of a Platform High Voltage Leak Detection Method for Drug Product Container Closure Integrity Testing Jason E. Fernandez, Biogen Polymers: E&L Considerations Moderator: Renaud Janssen, Datwyler Polymeric Materials in Primary Containers and Medical Devices A Lilly Perspective Karthik Vaideeswaran, Eli Lilly Advancing Flexibility, Softness and Transparency with Polybutene-1 for Parenteral Applications Isabelle Trocherie, LyondellBasell Effect of Ageing of Elastomeric Closures on their Physico/Chemical Properties and their Extractables Profile Bram Jongen, Datwyler Extractables and Leachables Evaluation of Single Use Systems for Biopharmaceuticals Moving Toward Standardization by Up-Coming USP <1665>/<665> Andreas Nixdorf, SGS Institut Fresenius 12:25 Q&A, Discussion Q&A, Discussion 13:00 Lunch Break, Poster Session & Exhibition CLOSING PLENARY Session 6 Latest in Manufacturing & Technology Moderator: Roger Asselta, Genesis Packaging Roman Mathaes, LONZA 14:00 Use of a Wireless Drone System for Improvement of Pharmaceutical Manufacturing Processes Joe Norris, SmartSkin David Brückner, F. Hoffmann-La Roche 14:30 State of Packaging and Testing Technology: Parenteral Cryo Solutions Chris Folta, Janssen 15:00 Coffee Break, Poster Session & Exhibition 15:30 Systematic Assessment of pccit Method Performance and Commonly Used Artificial Leaks Roman Mathaes, Lonza Christoph Herdlitschka, Wilco 16:00 Q&A, Discussion 16:30 End of Conference & Farewell 12 pda.org/eu/parpack2018

13 PDA Education Program 1 March 2018 Container Closure Development One-Day Training Course 1-2 March 2018 Container Closure Integrity Testing Two-Day Training Course 1-2 March 2018 Extractables & Leachables Two-Day Training Course

14 ONE-DAY TRAINING COURSE Container Closure Development Overview The course will give an overview on how to develop a container closure system for parenteral products. Starting with setting up a product profile of the final product container, all aspects will be covered, like selection of materials, assessment of container closure systems, specification and documentation of components and entire systems. In addition, current hot topics such as glass delamination and container closure integrity testing will be discussed. For all topics of the agenda presentations will be given. The participants are invited to add own experience, ask questions and offer issues to be discussed within the group and/or with the trainer. The intention is to work in an open workshop-like atmosphere. Who Should Attend: Scientists in Drug Product Development Scientists/ Engineers in Packaging Development Regulatory Affairs Experts Learning Objectives: Set-up of a target product profile of a container closure system Select appropriate container closure materials, components, and systems Apply the appropriate regulations and standards to container closure systems for parenteral formulations Prepare a development plan of a container closure systems from the early development until market phase Specify container closure systems regarding technical aspects and regulatory requirements Understand compendial requirements and quality as well as technical standards regarding container closure components and systems Jörg Zürcher, Senior Scientist, Bayer Jörg Zürcher is a pharmacist by education. After his studies and PhD thesis at the Free University in Berlin, he started his career in the pharmaceutical industry 1990 with the former Schering AG. He is responsible for the development of container closure systems and application devices at Bayer HealthCare and has more than 25 years experience in that field. His current focus is the development of systems/devices for liquid and parenteral as well as ophthalmic dosage forms. 14 pda.org/eu/ccd2018

15 TRAINING COURSE AGENDA 17 Jan 2018 Thursday, 1 March :00-17:00 9:00 Welcome & Introduction 9:30 Definitions Compendial definition Functional definition Components vs CCS Description of options Materials 9:45 Regulatory Background Ph.Eur. USP JP FDA Guideline EU Directive Relevant ectd sections 10:45 Coffee Break 11:15 Development of Container Closure Systems Set-up of target profile Packaging materials Modification of materials Extractables & Leachables (E&L) testing Permeability Light transmission Processability Functional testing Container closure integrity (CCI) Shipping assessment Combination products 12:30 Lunch Break 13:30 Workshop: Develop Your CCS 15:00 Coffee Break 15:30 Presentation of Workshop Results 16:00 Setting of Specifications / Submission Documentation Technical/ Quality specification Regulatory specification Technical drawing Regulatory drawing DMF for US submission 16:30 Wrap-up and Final Q&A 17:00 End of Training Course pda.org/eu/ccd

16 TWO-DAY WORKSHOP Container Closure Integrity Testing Overview This workshop focuses on theoretical and practical fundamentals of various CCI testing technologies and provides a systematic approach to apply these testing methods for CCI verification throughout drug product lifecycle. The Workshop will enable the participants to implement CCI testing strategies to ensure adequate drug product protection and be compliant with relevant regulatory and compendia requirements. In this Workshop, participants gain critical problem solving skills through: interactive discussions with a panel of cross-functional technical experts consisting of CCI testing laboratory experts, testing instrument suppliers/manufacturers, and pharmaceutical packaging development engineers hands-on testing training on the newest innovations and state-of-the-art instruments real-world case studies Who Should Attend Parenteral drug packaging engineers and formulation scientists Laboratory scientific staff and managers Parenteral manufacturing staff Sterility Quality Assurance Regulatory affair scientists Pharmaceutical packaging component manufacturing staff Presentation of Technology, Instruments Demo and Hands-on Training kindly supported by Genesis Packaging Technology, Lighthouse, Pfeiffer Vacuum, pti, Sartorius Stedim, Wilco Learning Objectives This workshop utilizes lectures, case studies, and interactive hands-on training on testing instruments to provide insight into the latest developments of Container Closure Integrity (CCI) Testing, with focus on achieving the following key objectives: Understanding up-to-date regulatory and pharmacopeia requirements on CCI. Defining CCI requirements for various container and drug product types using a risk-based approach. Explaining working principles of various CCI testing techniques and their practical applications, with focus on deterministic methods such as tracer gas detection (e.g. helium leak detection), electrical conductivity and capacitance (HVLD), vacuum decay leak detection, laserbased gas headspace analysis, mass extraction leak test. Selecting and applying appropriate testing methods for both laboratory and in-process testing to formulate comprehensive package integrity verification profiles. Defining CCI testing method development and validation approach and best practices. Avoiding common issues and pitfalls in CCI testing applications. Lei Li, Ph.D, Associate Engineer Advisor Delivery and Device R&D, Eli Lilly Lei Li currently serves as an engineer advisor at Delivery and Device R&D, Eli Lilly and Company. Lei has 9 years of experience in pharmaceutical and medical device industry, with focus on developing API and drug product packaging in support of clinical development and product commercialization, and establishing cold-chain distribution for biologic products. His current responsibilities include developing package integrity verification profiles for Lilly s diverse pipeline portfolio, developing and validating CCI testing methods, and supporting commercial control strategy development for CCI verification throughout drug product and device life cycle. He is a frequent speaker at PDA conferences and author of peer-reviewed articles and book chapters on CCI test methods. Lei Li received his Ph. D. in Analytical Chemistry from West Virginia University; prior to joining Eli Lilly, he worked at GE Plastics as an analytical and material scientist. 16 pda.org/eu/cci2018

17 WORKSHOP AGENDA Thursday, 1 March :00 17:30 9:00 Welcome and Introduction 9:15 Regulatory Requirements: CCI Introduction, Regulatory Requirements, and Industry Trends 9:45 CCI Assurance throughout Product Lifecycle Testing requirement definition risk based approach CCI Profile & Testing strategy development 10:30 Coffee Break 11:00 Introduction to Group Exercise #1: Product life cycle testing and method selection 11:15 CCI Test Methods: Fundamentals and Overview CCI defects and commonly used positive controls Sizing CCI defects using gas flow dynamics Evolution of CCI testing technology: liquid flow, gas flow, electron flow (electric current) 12:00 Lunch Break 13:00 CCI Test Methods: Fundamentals and Overview (continued) Deterministic vs probabilistic definitions Physicochemical methods vs microbiological methods: differences and correlations Microbial and Dye Ingress Testing Basics Seal Quality Testing Introduction group exercise #2: Method Characteristics 14:00 Advanced CCI Testing Technologies Vacuum and pressure decay Mass Extraction Headspace analysis HVLD 15:00 Coffee Break 15:30 CCI Testing Technologies (continued) Tracer gas (helium leak detection) Seal Integrity method example (residual seal force) 16:00 Current Topics: Industry Best-Practices and Novel Technologies 1. AMI Optical emission spectroscopy for CCI testing 2. API Container Testing using HeLD; Review Helium leak detection video 17:00 Group Exercise #2: Method Characteristics review, discussion Day 1 Review, Q&A 17:30 End of Day 1 Friday, 2 March :30 16:30 8:30 Application Case Studies Section 1 Vacuum and pressure decay Mass Extraction 9:10 Hands-on Training 9:50 Application Case Studies Section 2 Headspace analysis HVLD 10:30 Coffee Break 11:00 Application Case Studies Section 3 Tracer gas (helium leak detection) SQT (Residual Seal Force) 11:40 Instrument Demo and Hands-on Training 12:40 Lunch Break 13:40 Development and Validation of Integrity Test Methods Method development best practices Method validation strategy Pitfalls and solutions 14:30 Approaches to CCI Testing Method Selection Method selection considerations Class discussion - examples 15:00 Coffee Break 15:30 Group Exercise #1: Method Selection Review, Discussion, Q&A 16:00 Class Discussion, Recognition, Certification 16:30 End of Workshop Jennifer Roark, B.S., Manager Chemistry & Container Testing, Eurofins Medical Device Testing As Manager of Chemistry and Container Testing, Jennifer Roark oversees testing to support the container and package testing needs of both pharmaceutical and medical device clients. Her group specializes in various CCI testing technologies such as vacuum decay, high-voltage leak detection, FMS oxygen headspace, pressure decay, and dye immersion. She also supervises the physiochemical testing associated with the USP, EP, and JP General Chapters on plastics, elastomeric closures, glass, and container performance testing. Jennifer has more than 22 years of analytical testing experience and serves as one of Eurofins leading subject matter experts for Extractables and Leachables Testing. She currently serves on ASTM Committee E55 on the Manufacture of Pharmaceutical and Biopharmaceutical Products, Subcommittee E55.04 General Biopharmaceutical Standards, leading the efforts to draft standard WK Jennifer Roark has been involved with small molecule methods development and validation for over 12 years, and has co-published a series of articles on method validation. pda.org/eu/cci

18 TWO-DAY TRAINING COURSE Extractables & Leachables Including: Important Regulatory Updates Case Study Section: Selection of Toxikon s most interesting Case Studies, presented over the last 10 years! Overview When making Parenteral Drug Products, pharmaceutical companies are faced with the need to further investigate the materials that will be in contact with the drug product, either during manufacturing, intermediate storage, storage in its final packaging, or during the delivery of the drug to the patient. While historically, the potential safety issues were the main driver in these kinds of investigations, recently, also quality issues i.e. for biopharmaceuticals have become an additional concern. This workshop will look at Extractables & Leachables from many different angles: Definitions, Regulatory, Material & Polymer Science, Analytical E/L Methodologies, Safety Assessments, Study Design for different parenteral primary packaging systems, as well as for injection devices. Learning Objectives Upon completion of this workshop, you will be able to: Explain in detail the current regulatory requirements for container/closure qualification from an E/L perspective. Explain the upcoming changes in regulations, standards and recommendations from PQRI, USP and BPOG and how these changes could impact a future evaluation of a pharmaceutical C/C-system. Understand the materials of construction and their composition of container closure systems, and how they could impact the safety and quality of a parenteral drug product. Put together an evaluation program (review of provided documentation, analytical testing) of different types of parenteral drug product container/closure systems. Perform a safety/risk assessment of analytical results, obtained after completion of an E/L study. Who Should Attend Pharmaceutical Packaging and Device Engineers Production Engineers, using SU systems Regulatory Affairs Officers Pharmaceutical R & D Managers Analytical Chemists, working on E/L Quality Assurance Officers Dennis Jenke, PhD, Chief Executive Scientist, Triad Scientific Solutions Dennis Jenke is the Chief Executive Scientist for Triad Scientific Solutions, a provider of science-based solutions to plastic/product compatibility challenges associated with packaging, manufacturing equipment and delivery devices in the pharmaceutical, cosmetic, food and related industries. He was a Distinguished Scientist at Baxter Healthcare Corporation where for more than three decades he lead a team whose primary responsibility includes the assessment of material/product compatibility, specifically with respect to establishing the suitability for use of packaging systems, manufacturing systems and administration devices for pharmaceutical products (for example, extractables/leachables and product ingredient binding). He has published extensively in the areas of analytical chemistry, environmental science and material/solution compatibility and serves as an expert reviewer for numerous pharmaceutical and analytical journals. He is the author of the book Compatibility of Pharmaceutical Solutions and Contact Materials; Safety Considerations Associated with Extractables and Leachables and a contributing author to the Leachables and Extractables Handbook. Dennis Jenke is a member of numerous industry groups whose charter is to establish best demonstrated practices in the area of material/solution compatibility. 18 pda.org/eu/extractables-and-leachables2018

19 TRAINING COURSE AGENDA Thursday, 1 March :00 18:00 Introduction on Extractables & Leachables (E/L) What is the importance of a good E/L-qualification Historical cases of leachables, impacting the quality or the safety of a drug product Regulatory requirements (FDA, EMA ) for primary packaging Understanding the Materials, Used in the Manufacture of Pharmaceutical Containers & Closures Types of polymers examples in medical/pharmaceutical use Understanding the composition of polymers The issues with glass in parenteral applications Analytical Techniques to Perform Extractables & Leachables Research The importance of sample preparation: the corner stone in E/L research What are the target compounds for material research How does a classification of these compounds assist in finding the right analytical technique From basic screening methodologies to state-of-the-art equipment How to Set-up Extractables & Leachables Studies Selecting the right conditions for extraction How to select the right compounds to monitor in a leachable study Designing a leachable study FULL Session on Updates of E/L- Regulations, Standards and Recommendations Pharma Packaging: Preview of the final PQRI Parenteral Drug Product (DPD) & ODP Chemistry group Update on the most recent developments on the USP <661> chapters Devices Chemical characterization of devices according to ISO : What changes are coming up? Upcoming Revisions of the USP <87> and USP <88>: Where could it go to? (Bio)Pharmaceutical Manufacturing The BPOG protocol Where is USP with the update on the USP <661.3> Plastic Manufacturing Components standard How to Perform a Safety Evaluation Risk Assessment on Extractables & Leachables Toxicology 101 EMA Guideline on Genotoxic Impurities ICH M7 (DNA reactive Impurities) and its suggested staged approach The Threshold Concept of PQRI (OINDP and PDP/ODP) Examples Piet Christiaens, PhD, Scientific Director, Toxikon Europe Piet Christiaens received his Ph.D. from the Analytical Chemistry Department of the University of Leuven (Belgium) in From 1992 to 1997, he was Lab Manager in two Analytical Contract Laboratories. From 1997 to 2000, he worked as an independent consultant with Shell Chemical Company in Houston, Texas where he conducted research on a new hydrogenation catalyst system for Hydrogenated Triblock Co-Polymers (Kraton Polymers). Since 2001, Mr. Christiaens has been Scientific Director at Toxikon Europe where he develops analytical methods and protocols for both extractables and leachables studies for the Medical and Pharmaceutical Industries. Mr. Christiaens oversees all laboratory operations at Toxikon Europe and is also supports the European business development team. pda.org/eu/extractables-and-leachables

20 TRAINING COURSE AGENDA E/L Testing for a Pre-filled Syringe (Glass & Polymer) Glass Syringes: the issues with tungsten, glue residues and silicone oil and glass metals leaching The Issue with rubbers: the plunger, the needle shield or the tip cap: different approaches needed? The impact of secondary packaging option or necessity? Setting up extractable & leachable studies for a pre-filled Syringe E/L Testing for Lyophilized Drug Products Primary packaging for the lyophilized drug product modus of interaction with the DP Impact of the 21CFR Part 4 on combination products, used in the administration of a lyo DP Critical aspects when designing leachable studies for lyophilized DP Integration of the administration procedure (e.g. IV-set, pump system) in leachables evaluation How to Look at Injection Devices from an E/L Perspective Medical device regulations versus pharma packaging Test selection process for devices: What to do? USP and ISO series for biocompatibility testing Case: Injection device Large Volume Parenterals The challenge in E/L testing for LVP s Primary packaging for LVP s critical materials and components Secondary packaging for LVP: critical points to consider E/L Testing for Disposable and Single-Use Systems in Bioproduction Friday, 2 March :00 16:30 How to classify the risk of different single-use systems in the bioproduction process Understanding BPSA & BPOG recommendations, and how they can be implemented in the study design Performing E/L studies on filters: potential approaches John Iannone, Director of Extractables/Leachables and Impurities, Albany Molecular Research, Inc. (AMRI) John Iannone has a background in Biomedical Engineering from Boston University, where he later became a research engineer. Since going from Academia to Industry 13 years ago, John has assisted multiple pharmaceutical & medical device companies with the development of their product safety evaluation strategies. Previously a Technical Specialist at Toxikon, he now is the Director of Extractables/Leachables and Impurities at Albany Molecular Research, Inc (AMRI). His areas of expertise include Material Qualification & Biocompatibility, Extractables & Leachables, Chemical Characterization, and attainment of Biological or Toxicological risk assessments for medical devices, pharmaceutical container systems, bioprocessing systems, and combination products. John has given numerous technical presentations and has led several workshops on Extractable & Leachable Considerations, Biocompatibility, Microbiology, and Regulatory Testing Requirements. He also participates in the development of both industry groups recommendations and regulatory guidelines through Expert Panel membership, global Technical Committees, and industry collaborations. Additional responsibilities have included providing technical consultation to clients regarding unique testing requirements in an effort for them to meet global regulatory expectations. 20 pda.org/eu/extractables-and-leachables2018

21 INFORMATION VENUE Marriott Park Hotel Rome Via Colonnello Tommaso Masala Rome Italy Tel: DIRECTIONS GENERAL ADDRESS PDA Europe ggmbh Am Borsigturm Berlin, Germany Tel: Fax: CONFERENCE REGISTRATION HOURS Monday, 26 February: 9:00 17:00 Tuesday, 27 February: 8:00 17:30 Wednesday, 28 February: 8:00 12:00 COURSE REGISTRATION HOURS Thursday, 1 March: 8:00 16:30 Friday, 2 March: 8:00 12:00 Google For directions click on the picture, scan the QR-code or go to CONTACT INFORMATION Conference Inquiries Melanie Decker Director Events & Exhibitions decker@pda.org Conference Program Inquiries Sylvia Becker programs-europe@pda.org Registration Customer Care Tel: registration-europe@pda.org Education Program Inquiries Elke von Laufenberg training-europe@pda.org Exhibition/Sponsorship Inquiries Nadjeschda Gomez-Stahl Nadjeschda Gomez-Stahl expo-europe@pda.org TO EXHIBIT: Exhibition and Sponsorship Opportunities are available. PDA meetings and conferences are a great opportunity for your company to gain on-site exposure in front of highlyqualified,upper-level professionals in the pharmaceutical and biopharmaceutical industry. Exhibit at PDA events and let your company s products or services become a valuable tool or resource for our attendees. SPECIAL REQUIREMENTS If you require special accommodations to fully participate, please attach a written description of your needs with your registration form. Specific questions can be directed to registration-europe@pda.org. pda.org/eu/parpack

22 Parenteral Packaging Reg Form Page February 2018 Rome Italy Your registration is only complete upon filling in and submitting both pages of this form. 1 Registration All fees given in Euro, excluding VAT (22 %) 26 February Interest Group Meeting Meeting Fee Pre-filled Syringes All Participants February Interest Group Meeting Meeting Fee Packaging Science All Participants February Conference only Conference Fee Parenteral Packaging PDA Member 1595 **Nonmember 1895 * Early Bird 700 **Regulatory/Academic 800 Poster Presenter please mark here (written approval required, conference fee applies) 1 March One-Day Training Course Training Course Fee Container Closure Development All Participants March Two-Day Workshop Workshop Fee Container Closure Integrity All Participants March Two-Day Training Course Training Course Fee Extractables and Leachables All Participants 1495 The fee includes course documentation as well as mid-session refreshments and lunch. Excellent networking opportunities with snacks and drinks will be given. The fee does not include the hotel accommodation. PDA Europe has secured a limited number of rooms at a special group rate. **Registration fee includes a one-year PDA membership if no further special discount is granted. If you do not wish to join PDA and receive the benefits of membership, please check here (same rate applies). Group Registration Discount Register 5 colleagues for the conference at the same time and receive the 5th registration free. For more information on group discounts please contact Antje Petzholdt at petzholdt@ pda.org. Other discounts cannot be applied.. Discount for Exhibiting Companies Please mark here if your company is an exhibitor to this event and you will receive the conference ticket at the special price of 1095 Euro per ticket. No further discounts are applicable with this option (as PDA Membership Discount or Group Ticket discount). 22 pda.org/eu/parpack2018

23 Reg Form Page 2 Parenteral Packaging February 2018 Rome Italy 3 WAYS TO REGISTER ONLINE: pda.org/eu/parpack2018 FAX: registration-europe@pda.org 2 Your Contact Information If this form is an update to a previously submitted form, please check here. Mr. Ms. Dr. Nonmember I want to become a PDA Member. Please send me a subsription form Name (Last, First, MI) * PDA Member ID Number Job Title * Company* Department Mailing Address City Postal Code Country * Business Phone Fax Substituting for (Check only if you are substituting for a previously enrolled colleague; a nonmember substituting for member must pay the membership fee.) * This information will be published in the conference attendee list. Should you not wish us to publish these details, please contact us. 3 4 Information about Visa Matters Payment Options All registrations which will involve visa matters will have to be submitted to PDA EU four weeks prior to the start of the event at the latest. For later registrations, PDA Europe will be unable to assist participants in any visa affairs. All costs incurring in connection with visa affairs shall be borne by registrants. (This applies in particular to costs for submitting documents by courier.) Potential participants must be clients of UPS shipping agency and submit their UPS customer reference number to PDA EU (together with their registration). By Bank Transfer Beneficiary: PDA Europe ggmbh IBAN: DE BIC (SWIFT-Code): DEUTDEDBBER Bank Address: Deutsche Bank, Welfenallee 3-7, D Berlin, Germany By Credit Card American Express MasterCard VISA For your credit card information safety: Please send your details by fax only. Purchase Order Purchase Order Number Billing Address: Same as contact information address above. If not, please send your billing address to: petzholdt@pda.org Your Company VAT I.D.: This number starts by your country code with two characters (example: PDA Europe s country code starts with: DE followed by the number) PDA Europe VAT I.D.: DE Your registration is only complete upon filling in and submitting both pages of this form. Date Mandatory Signature CONFIRMATION: Transmitting your filled-in registration form constitutes a binding application for the specific event. PDA Europe will send you a confirmation including payment details. A legally binding contract is concluded once PDA Europe has sent a written invoice by mail to you. A letter of confirmation will be sent to you within one week once payment has been received. You must have this written confirmation to be considered enrolled for this PDA event. PDA Europe reserves the right to deny access to anyone unable to provide written confirmation that all dues have been fully settled. SUBSTITUTIONS: If you are unable to attend, substitutions are welcome and can be made at any time, including on site at the prevailing rate. If you are registering as a substitute attendee, please indicate this on the registration form. Changes are free of charge until 2 weeks prior to the start of the event. After this two-weeks period, there will be a charge of 100 per name change. REFUNDS: Refund requests must be sent to PDA Europe. If your written request is received on or before 7 January 2018, you will receive a full refund minus a 150 excl. VAT handling fee. After that time, no refund or credit requests will be approved. If you are an unpaid registrant and do not attend the event, you are responsible for paying the registration fee. On-site registrants are not guaranteed to receive conference materials until all advanced registered attendees receive them. PDA Europe works PCI-Compliant. EVENT CANCELLATION: PDA reserves the right to modify the material or speakers/instructors without notice, or to cancel an event. If an event must be canceled, registrants will be notified by PDA as soon as possible and will receive a full refund. PDA will not be responsible for airfare penalties or other costs incurred due to cancellation. For more details, contact PDA at info-europe@pda.org or fax to DOCUMENTATION: With your signature you give complete picture usage right to PDA and allow to film your exhibition space and intervention in the event, including the recording of your presentation for video purposes (with your slides, voice and image). This right extends also to the use of the resulting images in film documentation for webinars and similar items produced by PDA. pda.org/eu/parpack

24 P D A E U R O P E E V E N T S 26 February 26 February February Interest Group Meeting Pre-filled Syringes Interest Group Meeting Packaging Science Parenteral Packaging IG IG Rome, Italy 13 April Interest Group Meeting Visual Inspection IG Berlin, Germany April Training Course Quality Culture Transformation Resources Course TC Mainz, Germany April Training Course Freeze Drying in Practice TC Osterode (Harz) Germany April Vaccines Málaga, Spain 7 May 8-9 May Interest Group Meeting Advanced Virus Detection Technologies Virus Forum IG Florence, Italy May Pharmacopoeia Conference Vienna, Austria 5-6 June Advanced Therapy Medicinal Products Amsterdam, The Netherlands 25 June 25 June June Interest Group Meeting Quality Systems Interest Group Meeting Freeze Drying 3rd PDA Europe Annual Meeting IG IG Berlin, Germany October Pharmaceutical Microbiology Berlin, Germany October Visual Inspection Forum Berlin, Germany 6-7 November Outsourcing & Supply Chain - A 360 View Seville, Spain November Pharmaceutical Freeze Drying Technology Seville, Spain November 11 th Workshop on Monoclonal Antibodies Seville, Spain Subject to change For latest info: europe.pda.org Shortlist 17 Jan 2018 Events with additional Education Program. More information europe.pda.org Connecting People, Science and Regulation General Information PDA Europe ggmbh Am Borsigturm Berlin, Germany Tel: Fax: info-europe@pda.org europe. pda.org